Johnson & Johnson (JNJ)
NYSE: JNJ · Real-Time Price · USD
190.30
-0.10 (-0.05%)
At close: Oct 27, 2025, 4:00 PM EDT
190.58
+0.28 (0.15%)
After-hours: Oct 27, 2025, 7:59 PM EDT
Johnson & Johnson Employees
Johnson & Johnson had 138,100 employees as of December 31, 2024. The number of employees increased by 6,200 or 4.70% compared to the previous year.
Employees
138,100
Change (1Y)
6,200
Growth (1Y)
4.70%
Revenue / Employee
$667,263
Profits / Employee
$181,890
Market Cap
457.53B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 138,100 | 6,200 | 4.70% |
| Dec 31, 2023 | 131,900 | -20,800 | -13.62% |
| Dec 31, 2022 | 152,700 | 11,000 | 7.76% |
| Dec 31, 2021 | 141,700 | 7,200 | 5.35% |
| Dec 31, 2020 | 134,500 | 2,300 | 1.74% |
| Dec 29, 2019 | 132,200 | -2,900 | -2.15% |
| Dec 30, 2018 | 135,100 | 1,100 | 0.82% |
| Dec 31, 2017 | 134,000 | 7,600 | 6.01% |
| Dec 31, 2016 | 126,400 | -700 | -0.55% |
| Dec 31, 2015 | 127,100 | 600 | 0.47% |
| Dec 28, 2014 | 126,500 | -1,600 | -1.25% |
| Dec 29, 2013 | 128,100 | 500 | 0.39% |
| Dec 30, 2012 | 127,600 | 9,700 | 8.23% |
| Dec 31, 2011 | 117,900 | 3,900 | 3.42% |
| Dec 31, 2010 | 114,000 | -1,500 | -1.30% |
| Dec 31, 2009 | 115,500 | -3,200 | -2.70% |
| Dec 28, 2008 | 118,700 | -500 | -0.42% |
| Dec 30, 2007 | 119,200 | -3,000 | -2.45% |
| Dec 31, 2006 | 122,200 | 6,600 | 5.71% |
| Dec 31, 2005 | 115,600 | 5,600 | 5.09% |
| Dec 31, 2004 | 110,000 | -1,000 | -0.90% |
| Dec 28, 2003 | 111,000 | 3,000 | 2.78% |
| Dec 29, 2002 | 108,000 | 6,000 | 5.88% |
| Dec 30, 2001 | 102,000 | 1,000 | 0.99% |
| Dec 31, 2000 | 101,000 | 3,200 | 3.27% |
| Dec 31, 1999 | 97,800 | 4,700 | 5.05% |
| Dec 31, 1998 | 93,100 | 2,600 | 2.87% |
| Dec 28, 1997 | 90,500 | 1,200 | 1.34% |
| Dec 29, 1996 | 89,300 | 7,000 | 8.51% |
| Dec 31, 1995 | 82,300 | 800 | 0.98% |
| Dec 31, 1994 | 81,500 | -100 | -0.12% |
| Dec 31, 1993 | 81,600 | -3,300 | -3.89% |
| Dec 31, 1992 | 84,900 | 2,200 | 2.66% |
| Dec 31, 1991 | 82,700 | 500 | 0.61% |
| Dec 31, 1990 | 82,200 | -900 | -1.08% |
| Dec 31, 1989 | 83,100 | 1,800 | 2.21% |
| Dec 31, 1988 | 81,300 | 3,100 | 3.96% |
| Dec 31, 1987 | 78,200 | 1,100 | 1.43% |
| Dec 31, 1986 | 77,100 | 2,200 | 2.94% |
| Dec 31, 1985 | 74,900 | 700 | 0.94% |
| Dec 31, 1984 | 74,200 | -3,200 | -4.13% |
| Dec 31, 1983 | 77,400 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| Danaher | 63,000 |
JNJ News
- 15 hours ago - New study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile - PRNewsWire
- 15 hours ago - TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years - PRNewsWire
- 15 hours ago - Icotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis - PRNewsWire
- 3 days ago - Published in The Lancet: Nipocalimab significantly decreased Sjögren's disease (SjD) activity and severity through substantial reduction in Sjögren's-related autoantibodies - PRNewsWire
- 3 days ago - Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis - PRNewsWire
- 3 days ago - Smart Acquisitions And Profit Margin Growth Amid Strategic Repositioning - Seeking Alpha
- 4 days ago - These low-risk stocks could be a profitable answer to this volatile earnings season - Market Watch
- 5 days ago - Johnson & Johnson to Participate in the 7th Annual Wolfe Research Healthcare Conference - Business Wire